Share on LinkedInShare on LinkedIn

ARTICLE · 31 OCTOBER 2025

Divergent Claim Construction Results In Discretionary Denial

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

In a recent decision, Acting Director Coke Morgan Stewart granted Patent Owner's request for discretionary denial in Sun Pharmaceuticals Industries Inc. v. Nivagen Pharmaceuticals, Inc., IPR2025-00893.

United StatesIntellectual Property

In a recent decision, Acting Director Coke Morgan Stewart granted Patent Owner's request for discretionary denial in Sun Pharmaceuticals Industries Inc. v. Nivagen Pharmaceuticals, Inc., IPR2025-00893. While some factors weighed against denial, the Acting Director emphasized Patent Owner's different claim construction positions in the current proceeding and the parallel district court case as favoring denial.

On April 22, 2025, Sun Pharmaceuticals Industries Inc. ("Petitioner") filed a petition requesting an inter partes review of U.S. Patent No. 11,878,076 ("the '076 Patent") directed to compositions of phenobarbital. On July 18, 2025, Nivagen Pharmaceuticals, Inc. ("Patent Owner") filed a request for discretionary denial arguing that the IPR should be discretionarily denied partly because the projected final written decision would issue before the parallel district court trial.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from